Lobbying Filing Details

Total Spending

$40,000

Activities

3

Lobbyists

2

Gov't Entities

5

Filing Information

Filing UUID:: 6013b349-1af6-4370-aee3-97ab6817cb07
Type:: Q2 - 2nd Quarter - Report
Period:: 2026 - 2nd Quarter (Apr 1 - June 30)
Date Posted:: July 15, 2026 at 6:29 PM
Income:: $40,000
Expenses:: $0
Document URL:: View Submission

Quick Info

Document Type: text/html
Posted By: Don Kent

Registrant

THE NICKLES GROUP, LLC

Consulting firm.

Washington, District of Columbia

Client

EMERGENT BIOSOLUTIONS

Pharmaceutical company.

Maryland, United States of America

Lobbying Activities (3)

Activity 1

Budget/Appropriations

Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield. Opioid and heroin addiction legislation, naloxone access and awareness.

Lobbyists (1)

MR. DONALD KENT

Government Entities (1)

SENATE

Activity 2

Defense

S. 4784, the FY27 National Defense Authorization Act provisions related to biological and chemical defense and access to naloxone.

Lobbyists (1)

MR. DONALD KENT

Government Entities (1)

SENATE

Activity 3

Health Issues

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield, Opioid crisis legislation, naloxone access and awareness, H.R. 8800 / S. 4784, the FY27 National Defense Authorization Act provisions related to biological and chemical defense and access to naloxone.

Lobbyists (2)

MARY BETH SAVARY TAYLOR
MR. DONALD KENT

Government Entities (3)

SENATE
HOUSE OF REPRESENTATIVES
Office of Management & Budget (OMB)

Source: LDA.gov, data retrieved November 4, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.